Worth reading
33Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
Antibody research supportAntibody and reagent sales
Applicable field (uses covered by this announcement)
Antibody research support; antibody and reagent sales
Launch date7 October 2026 (scheduled exhibition start date)
Location (as indicated in this announcement)
Pacifico Yokohama (BioJapan2026 venue)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
BioJapan2026 website (https://jcd-expo.jp/jp/)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Antibody research support, Antibody and reagent sales |
| Launch date | 7 October 2026 (scheduled exhibition start date) |
| Applicable area | Antibody research support; antibody and reagent sales |
| Location | Pacifico Yokohama (BioJapan2026 venue) |
| Source | BioJapan2026 website (https://jcd-expo.jp/jp/) |
Items this document does not state (13)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To introduce products and services related to antibody research support and antibody and reagent sales.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.